- Home
- STHO vs YARW Comparison
STHO vs YARW Comparison
Compare STHO & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STHO | YARW |
|---|---|---|
| Founded | 2022 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 111.2M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | STHO | YARW |
|---|---|---|
| Price | $9.49 | $42.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 14.1K | ★ 20.4K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.73 | ★ 33.33 |
| EPS | ★ 2.58 | N/A |
| Revenue | ★ $110,143,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.08 | $31.55 |
| 52 Week High | $9.78 | $44.28 |
Technical Indicators
Market Signals| Indicator | STHO | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 56.45 | 82.52 |
| Support Level | $8.71 | N/A |
| Resistance Level | $9.68 | $44.28 |
| Average True Range (ATR) | 0.24 | 3.48 |
| MACD | 0.01 | 0.82 |
| Stochastic Oscillator | 50.00 | 82.55 |
Price Performance
Historical ComparisonAbout STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties, and land and development properties.
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.